John T. Isaacs
Affiliations: | Johns Hopkins University, Baltimore, MD |
Area:
Pharmacology, Pharmaceutical Chemistry, Cell BiologyGoogle:
"John Isaacs"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Ashani Weeraratna | grad student | (BME Tree) | |
| Ivan V. Litvinov | grad student | 2006 | Johns Hopkins |
| Pratap Singh | grad student | 2008 | Johns Hopkins |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jasmine S, Mandl A, Krueger TEG, et al. (2024) Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. The Prostate |
| Labrecque MP, Brown LG, Coleman IM, et al. (2023) Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. The Prostate |
| Isaacs JT, Dalrymple SL, Antony L, et al. (2023) Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. The Prostate |
| Isaacs JT. (2023) Consequence of evolutionary loss of seasonal breeding by humans for prostate cancer chemoprevention. American Journal of Clinical and Experimental Urology. 11: 194-205 |
| Lawrence MG, Taylor RA, Cuffe GB, et al. (2023) The future of patient-derived xenografts in prostate cancer research. Nature Reviews. Urology |
| Patterson JC, Varkaris A, Croucher PJP, et al. (2022) Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research |
| Sena LA, Kumar R, Sanin DE, et al. (2022) Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation |
| Sena LA, Brennen WN, Isaacs JT. (2022) There are gremlins in prostate cancer. Nature Cancer. 3: 530-531 |
| Isaacs JT, Brennen WN, Christensen SB, et al. (2021) Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. Molecules (Basel, Switzerland). 26 |
| Kumar R, Mendonca J, Owoyemi O, et al. (2021) Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Research |